This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sunesis Pharmaceuticals Inc (SNSS)

NASDAQ: Health Care

Company Cash Flow
Dec 2014 Dec 2013 Dec 2012 Dec 2011
Cash Flow From Operating Activities
Net Income (Loss) -43.00M -34.60M -43.95M -20.14M
Operating Gains/Losses 0.00 0.00 -93.00K 211.00K
Extraordinary Gains / Losses 0.00 0.00 0.00 0.00
(Increase) Decrease In Receivables 0.00 0.00 0.00 0.00
(Increase) Decrease in Inventories 0.00 0.00 0.00 0.00
(Increase) Decrease In Other Current Assets 0.00 0.00 0.00 0.00
(Decrease) Increase In Payables 2.22M 875.00K -580.00K 242.00K
(Decrease) Increase In Other Current Liabilities 604.00K -521.00K 3.79M 1.57M
(Increase) Decrease In Other Working Capital -5.69M -7.96M 19.62M 0.00
Other Non-Cash Items 2.33M 3.65M 10.23M -4.49M
Net Cash From Continuing Operations -43.18M -37.42M -10.64M -22.84M
Net Cash From Discontinued Operations 0.00 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities -43.18M -37.42M -10.64M -22.84M
Sale of Property, Plant & Equipment 0.00 0.00 11.00K 34.00K
Cash Used for Investing Activities
Sale of Short-Term Investments 45.84M 59.11M 46.23M 0.00
Purchases of Property, Plant & Equipment -48.00K 0.00 0.00 -15.00K
Acquisitions 0.00 0.00 0.00 0.00
Purchases of Short-Term Investments -42.46M -26.89M -67.61M -52.08M
Other Cash from Investing Activities 0.00 0.00 0.00 0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities 3.33M 32.22M -21.37M 4.18M
Issuance of Debt 0.00 0.00 14.98M 9.62M
Cash Used for Financing Activities
Issuance of Capital Stock 56.28M 12.57M 22.66M 4.12M
Repayment of Long-Term Debt -9.36M -7.18M 0.00 0.00
Repurchase of Capital Stock 0.00 0.00 0.00 0.00
Payment of Cash Dividends 0.00 0.00 0.00 0.00
Other Financing Charges, Net 0.00 0.00 0.00 0.00
Net Cash From Financing Activities 46.92M 5.39M 37.64M 13.75M
Effect of Exchange Rate Changes 0.00 0.00 0.00 0.00
Net Change in Cash & Cash Equivalents 7.07M 181.00K 5.63M -4.91M

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

SNSS Sunesis Pharmaceuticals Inc

Chart of SNSS

Analysts Ratings for SNSS

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 0 0 0 0
Moderate Buy 0 0 0 0
Hold 3 4 5 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 1 2

SNSS Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs